


MMAF sodium (GMP)

Cat. No.:	HY-15579BG
CAS No.:	1799706-65-2
Molecular Formula:	C ₃₉ H ₆₄ N ₅ NaO ₈
Molecular Weight:	753.94
Target:	Microtubule/Tubulin; ADC Cytotoxin
Pathway:	Cell Cycle/DNA Damage; Cytoskeleton; Antibody-drug Conjugate/ADC Related
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

MMAF sodium GMP is a GMP grade MMAF (sodium) (HY-15579B). MMAF sodium (Monomethylauristatin F sodium) is a potent tubulin polymerization inhibitor and is used as an antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A^{[1][2][3]}

CUSTOMER VALIDATION

- J Control Release. 2018 May 10;277:48-56.
- Mol Ther Nucleic Acids. 2018 Mar 2;10:227-236.
- Mol Cancer Ther. 2023 Jan 31;MCT-22-0440.
- Target Oncol. 2019 Oct;14(5):577-590.
- Research Square Print. 2023 Jan 6th.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Lee JW, et al. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res. 2010 May 1;16(9):2562-70.
- [2]. Lee JJ, et al. Enzymatic prenylation and oxime ligation for the synthesis of stable and homogeneous protein-drug conjugates for targeted therapy. Angew Chem Int Ed Engl. 2015 Oct 5;54(41):12020-4.
- [3]. Kim EG, et al. Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics.
- [4]. Doronina SO, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006 Jan-Feb;17(1):114-24.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA